Praxis Precision Medicines, Inc. PRAX
330.23 USD -15.98 (-4.62%)
Nov 12, 2026, 3:34 PM EST
319.34 Day range 343.71
164.09 52-week range 386.33
- YTD
- +12.04%
- 1 year
- +79.85%
News
seekingalpha.com Praxis Precision Medicines, Inc. (PRAX) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript Praxis Precision Medicines, Inc. ( PRAX ) 3rd Annual Guggenheim Healthcare Innovation Conference November 9, 2026 9:30 AM EST Company Participants Marcio Souza - President, CEO & Director Tim Kelly -…
benzinga.com RBC Capital Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $478 RBC Capital analyst Leonid Timashev maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and raises the price target from $462 to $478.- benzinga.com Wedbush Maintains Underperform on Praxis Precision Medicine, Raises Price Target to $189 Wedbush analyst Laura Chico maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Underperform and raises the price target from $188 to $189.
benzinga.com Wells Fargo Maintains Equal-Weight on Praxis Precision Medicine, Lowers Price Target to $343 Wells Fargo analyst Benjamin Burnett maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Equal-Weight and lowers the price target from $362 to $343.- benzinga.com BTIG Reiterates Buy on Praxis Precision Medicine, Maintains $826 Price Target BTIG analyst Kambiz Yazdi reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $826 price target.
globenewswire.com Praxis Precision Medicines Provides Corporate Update and Reports Third Quarter 2026 Financial Results FDA reviews of relutrigine, with PDUFA target action date of December 27, 2026, and ulixacaltamide HCI, with PDUFA target action date of January 29, 2027, are ongoing Topline results from the EMERALD…
benzinga.com KKR, Constellation Energy On Deck Monday As Private Credit, Power Face Test KKR headlines Monday’s reports, with investors weighing whether fundraising momentum can offset a sharp year-to-date stock decline. Constellation Energy, Barrick Mining, Ferguson Enterprises and ORIX…
benzinga.com JP Morgan Initiates Coverage On Praxis Precision Medicine with Overweight Rating, Announces Price Target of $700 JP Morgan analyst Tessa Romero initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Overweight rating and announces Price Target of $700.
benzinga.com HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1201 Price Target HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $1201 price target.
benzinga.com HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1201 Price Target HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $1201 price target.
benzinga.com BTIG Maintains Buy on Praxis Precision Medicine, Raises Price Target to $826 BTIG analyst Kambiz Yazdi maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $810 to $826.
benzinga.com Praxis Precision Medicine Q2 2026 Earnings Call Transcript Praxis Precision Medicine (NASDAQ:PRAX) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. Benzinga APIs provide real-time access…- benzinga.com HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1201 Price Target HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $1201 price target.
- benzinga.com Needham Reiterates Buy on Praxis Precision Medicine, Maintains $582 Price Target Needham analyst Ami Fadia reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $582 price target.
- benzinga.com Goldman Sachs Maintains Buy on Praxis Precision Medicine, Raises Price Target to $575 Goldman Sachs analyst Kevin Strang maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $470 to $575.
benzinga.com RBC Capital Maintains Outperform on Praxis Precision Medicine, Raises Price Target to $462 RBC Capital analyst Leonid Timashev maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and raises the price target from $449 to $462.- benzinga.com Wells Fargo Maintains Equal-Weight on Praxis Precision Medicine, Raises Price Target to $362 Wells Fargo analyst Benjamin Burnett maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Equal-Weight and raises the price target from $323 to $362.
benzinga.com Needham Maintains Buy on Praxis Precision Medicine, Raises Price Target to $582 Needham analyst Ami Fadia maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $575 to $582.
benzinga.com Motorola Solutions Posts Upbeat Q2 Earnings, Joins Insmed, Diodes, Parker-Hannifin And Other Big Stocks Moving Higher On Thursday US stocks mixed on Thurs. Dow Jones down 50 pts. Motorola Solutions Inc shares up 9.5% after reporting strong Q2 results & raised guidance.- benzinga.com Praxis Precision Medicine Q2 EPS $(2.87) Beats $(3.65) Estimate Praxis Precision Medicine (NASDAQ:PRAX) reported quarterly losses of $(2.87) per share which beat the analyst consensus estimate of $(3.65) by 21.37 percent. This is a 13.29 percent increase over…
benzinga.com BTIG Reiterates Buy on Praxis Precision Medicine, Maintains $810 Price Target BTIG analyst Kambiz Yazdi reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $810 price target.- benzinga.com Goldman Sachs Initiates Coverage On Praxis Precision Medicine with Buy Rating, Announces Price Target of $447 Goldman Sachs analyst Kevin Strang initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Buy rating and announces Price Target of $447.
- benzinga.com Praxis Precision Medicines And Remagine Labs Announce Research Collaboration And License Agreement To Develop Iontophoretic Transdermal Patch For Delivery Of Ulixacaltamide For Essential Tremor Collaboration aims to quickly enable ulixacaltamide to be delivered via active transdermal route Potential to expand the addressable market for ulixacaltamide beyond the initial patient population…
- benzinga.com Praxis Precision Medicines Announces FDA Extends PDUFA Date To December 27, 2026 For Relutrigine Following Major Amendment Submission; No New Clinical Or Safety Concerns Cited FDA sets updated PDUFA date of December 27, 2026BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ:PRAX), a fully integrated, leading central nervous system (CNS)…
benzinga.com Applied Materials To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Monday Top Wall Street analysts upgraded and downgraded several top companies, including Applied Materials, Robinhood, Liquidia, Airbnb, Praxis, Alnylam, and Uniqure.- benzinga.com Needham Maintains Buy on Praxis Precision Medicine, Raises Price Target to $575 Needham analyst Ami Fadia maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $537 to $575.
benzinga.com Praxis' Seizure Drug Move Towards Faster Development After Positive Trial Results FDA grants Breakthrough Therapy Designation to Praxis' elsunersen after strong seizure reduction data in SCN2A-DEE.- benzinga.com Praxis Precision Medicines Receives Breakthrough Therapy Designation From FDA For Elsunersen To Treat Seizures Associated With SCN2A Development And Epileptic Encephalopathy Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that the U.S. Food and Drug…
- benzinga.com RBC Capital Initiates Coverage On Praxis Precision Medicine with Outperform Rating, Announces Price Target of $449 RBC Capital analyst Leonid Timashev initiates coverage on Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform rating and announces Price Target of $449.
- benzinga.com Oppenheimer Maintains Outperform on Praxis Precision Medicine, Lowers Price Target to $650 Oppenheimer analyst Jay Olson maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and lowers the price target from $750 to $650.
- benzinga.com Truist Securities Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $616 Truist Securities analyst Danielle Brill maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and lowers the price target from $715 to $616.
- benzinga.com Deutsche Bank Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $374 Deutsche Bank analyst David Hoang maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and lowers the price target from $420 to $374.
- benzinga.com Wedbush Maintains Underperform on Praxis Precision Medicine, Lowers Price Target to $162 Wedbush analyst Laura Chico maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Underperform and lowers the price target from $166 to $162.
benzinga.com CrowdStrike To Gain 7%? Here Are 10 Top Analyst Forecasts For Tuesday Wall Street analysts change ratings for top stocks: CRWD price target raised, FULC target lowered, HPQ target raised, PRAX target cut, GNSS target raised, INTU target lowered, GH target raised, CRDO…- benzinga.com Baird Maintains Outperform on Praxis Precision Medicine, Lowers Price Target to $400 Baird analyst Joel Beatty maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Outperform and lowers the price target from $433 to $400.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com HC Wainwright & Co. Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $1201 HC Wainwright & Co. analyst Douglas Tsao maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and lowers the price target from $1245 to $1201.
benzinga.com Praxis Reassesses Vormatrigine Program After Pivotal Epilepsy Study Misses Primary Endpoint Praxis Precision Medicines reports mixed Phase 2/3 POWER1 results for vormatrigine, with higher-dose data showing stronger seizure reduction.- benzinga.com BTIG Maintains Buy on Praxis Precision Medicine, Lowers Price Target to $810 BTIG analyst Kambiz Yazdi maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and lowers the price target from $843 to $810.
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session
- benzinga.com Praxis Precision's Phase 2/3 POWER1 Study Of Vormatrigine In Focal Onset Seizures Did Not Meet Its Primary Endpoint, Though 50% Response Rate Was Achieved And Seizure Reduction Was More Pronounced At 30 Mg Dose In Second Half Of The Study POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measureSecondary measure, the 50% response rate, was met and seizure reduction during the second…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $1245 Price Target HC Wainwright & Co. analyst Douglas Tsao reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $1245 price target.
- benzinga.com BTIG Reiterates Buy on Praxis Precision Medicine, Maintains $843 Price Target BTIG analyst Kambiz Yazdi reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $843 price target.
- benzinga.com Truist Securities Maintains Buy on Praxis Precision Medicine, Raises Price Target to $715 Truist Securities analyst Danielle Brill maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $700 to $715.
- benzinga.com Wedbush Maintains Underperform on Praxis Precision Medicine, Raises Price Target to $166 Wedbush analyst Laura Chico maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Underperform and raises the price target from $130 to $166.
- benzinga.com BTIG Reiterates Buy on Praxis Precision Medicine, Maintains $843 Price Target BTIG analyst Kambiz Yazdi reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $843 price target.
- benzinga.com Praxis Precision Medicine Q1 EPS $(3.20) Beats $(3.50) Estimate Praxis Precision Medicine (NASDAQ:PRAX) reported quarterly losses of $(3.20) per share which beat the analyst consensus estimate of $(3.50) by 8.57 percent. This is a 2.74 percent increase over…
benzinga.com Why Is Praxis Precision Stock Soaring Tuesday? Praxis (PRAX) shares jump as FDA accepts NDA for ulixacaltamide in essential tremor. Target action date set for Jan 2027. Read more here.
benzinga.com Needham Reiterates Buy on Praxis Precision Medicine, Maintains $510 Price Target Needham analyst Ami Fadia reiterates Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and maintains $510 price target.- benzinga.com Praxis Precision Medicines' New Drug Application For Ulixacaltamide HCI Receives FDA Acceptance For Review To Treat Essential Tremor Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that the U.S. Food and Drug…